Diabetes News

SGLT2 inhibitors and GLP-1 were more effective than dipeptidyl peptidase-4 inhibitors and sulfonylurea kidney complications .

Canagliflozin was associated with increased iron utilization and improved hemoglobin levels for adults with type 2 diabetes and chronic kidney disease, according to data published in Nephrology Dialysis Transplantation.

Acetazolamide was associated with an acute, reversible drop in GFR without impacting glucose metabolism for adults with type 1 diabetes and preserved kidney function, according to study data.

Follow-up albuminuria testing can be an important step in kidney care following initial abnormal results from a urine protein dipstick test, according to an analysis of health records.

Long-term albuminuria risks for U.S. adults with Asian/Pacific Islander ancestry who have diabetes and normal kidney function differ across ethnic subgroups, according to data published in Kidney Medicine.

Decreases in body weight and HbA1c induced by GLP-1 receptor agonists and other diabetes drugs can reduce the risk for cardiometabolic complications for adults newly diagnosed with type 2 diabetes, researchers reported.

A county-level assessment of deaths from cardio-kidney-metabolic disease and social determinants of health revealed that particular determinants are more or less important in different U.S. regions, researchers reported in JAMA.

SGLT2 inhibitors were associated with similar renal and CV outcomes vs. GLP-1 receptor agonists for patients with diabetes, regardless of chronic kidney disease status, researchers reported.

Adults with type 2 diabetes have lower risks for death and major adverse cardiovascular and kidney events if they use tirzepatide compared with GLP-1 receptor agonists, according to observational data published in JAMA Network Open.